Cellebrite DI Ltd. (NASDAQ:CLBT) is Josh Arnold Investment Consultant LLC's 9th Largest Position

Josh Arnold Investment Consultant LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 99.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,850 shares of the company's stock after purchasing an additional 29,850 shares during the period. Cellebrite DI makes up approximately 0.8% of Josh Arnold Investment Consultant LLC's investment portfolio, making the stock its 9th biggest position. Josh Arnold Investment Consultant LLC's holdings in Cellebrite DI were worth $1,008,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CLBT. Point72 Asia Singapore Pte. Ltd. increased its position in Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock worth $33,000 after purchasing an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock worth $52,000 after buying an additional 1,742 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Cellebrite DI in the 2nd quarter valued at $71,000. Pathway Financial Advisers LLC boosted its holdings in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock valued at $74,000 after acquiring an additional 4,118 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in Cellebrite DI during the 2nd quarter worth $103,000. 45.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Bank of America increased their target price on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Lake Street Capital lifted their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. TD Cowen raised their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Monday, September 23rd. Finally, Craig Hallum boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $20.29.

Cellebrite DI Price Performance

NASDAQ CLBT traded up $0.29 during mid-day trading on Friday, reaching $20.18. 1,052,063 shares of the stock were exchanged, compared to its average volume of 1,798,695. The stock has a 50 day simple moving average of $18.22 and a 200-day simple moving average of $15.16. The stock has a market cap of $4.16 billion, a P/E ratio of -13.02, a P/E/G ratio of 2.75 and a beta of 1.50. Cellebrite DI Ltd. has a one year low of $7.91 and a one year high of $21.00.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to analysts' expectations of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm's quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.09 EPS. Sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.32 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.